{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:08:51Z","timestamp":1791299331526,"version":"4.1.0"},"reference-count":222,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","aaojournal.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.ophtha.2017.04.028","type":"journal-article","created":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T14:16:13Z","timestamp":1498313773000},"page":"1690-1711","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":166,"title":["Myopic Choroidal Neovascularization"],"prefix":"10.1016","volume":"124","author":[{"given":"Chui Ming Gemmy","family":"Cheung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer J.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank G.","family":"Holz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyu Hyung","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy Y.Y.","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Ohno-Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Jen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien Yin","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2017.04.028_bib2","unstructured":"Hammond CJ. Myopia prevalence in Europe: cohort effect of increasing prevalence not fully explained by higher educational levels. The Association for Research in Vision and Ophthalmology 2014 Annual Meeting. Orlando, Florida, May 4\u20138,\u00a02014."},{"key":"10.1016\/j.ophtha.2017.04.028_bib3","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/00006324-200104000-00012","article-title":"Does education explain ethnic differences in myopia prevalence? A population-based study of young adult males in Singapore","volume":"78","author":"Wu","year":"2001","journal-title":"Optom Vis Sci"},{"key":"10.1016\/j.ophtha.2017.04.028_bib4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1755-3768.1988.tb02657.x","article-title":"Nation-wide survey of myopia among schoolchildren in Taiwan, 1986","volume":"185","author":"Lin","year":"1988","journal-title":"Acta Ophthalmol Suppl"},{"key":"10.1016\/j.ophtha.2017.04.028_bib5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00006324-199905000-00013","article-title":"Epidemiologic study of ocular refraction among schoolchildren in Taiwan in 1995","volume":"76","author":"Lin","year":"1999","journal-title":"Optom Vis Sci"},{"key":"10.1016\/j.ophtha.2017.04.028_bib6","first-page":"684","article-title":"Epidemiologic study of the prevalence and severity of myopia among schoolchildren in Taiwan in 2000","volume":"100","author":"Lin","year":"2001","journal-title":"J\u00a0Formos Med Assoc"},{"key":"10.1016\/j.ophtha.2017.04.028_bib7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.47102\/https:\/\/doi.org\/10.47102\/annals-acadmedsg.V33N1p27","article-title":"Prevalence of myopia in Taiwanese schoolchildren: 1983 to 2000","volume":"33","author":"Lin","year":"2004","journal-title":"Ann Acad Med Singapore"},{"key":"10.1016\/j.ophtha.2017.04.028_bib8","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1167\/iovs.09-3455","article-title":"Refractive error and biometry in older Chinese adults: the Liwan Eye Study","volume":"50","author":"He","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2017.04.028_bib9","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1167\/iovs.03-1051","article-title":"Refractive error and visual impairment in urban children in southern china","volume":"45","author":"He","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2017.04.028_bib10","first-page":"2486","article-title":"Prevalence and risk factors for refractive errors in adult Chinese in Singapore","volume":"41","author":"Wong","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2017.04.028_bib11","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1167\/iovs.13-11725","article-title":"Prevalence of refractive errors in a multiethnic Asian population: the Singapore epidemiology of eye disease study","volume":"54","author":"Pan","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2017.04.028_bib12","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ajo.2012.02.027","article-title":"Variation in prevalence of myopia between generations of migrant Indians living in Singapore","volume":"154","author":"Pan","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib13","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1001\/archophthalmol.2011.230","article-title":"Prevalence and characteristics of myopic retinopathy in a rural Chinese adult population: the Handan Eye Study","volume":"129","author":"Gao","year":"2011","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib14","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.ajo.2013.01.009","article-title":"Racial variations in the prevalence of refractive errors in the United States: the Multi-Ethnic Study of Atherosclerosis","volume":"155","author":"Pan","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib15","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.ophtha.2006.11.034","article-title":"Morphology and long-term changes of choroidal vascular structure in highly myopic eyes with and without posterior staphyloma","volume":"114","author":"Moriyama","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.04.028_bib16","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.preteyeres.2015.12.001","article-title":"Updates of pathologic myopia","volume":"52","author":"Ohno-Matsui","year":"2016","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ophtha.2017.04.028_bib17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ajo.2013.08.010","article-title":"Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review","volume":"157","author":"Wong","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib18","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.preteyeres.2012.04.001","article-title":"Choroidal neovascularization in pathological myopia","volume":"31","author":"Neelam","year":"2012","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.ophtha.2017.04.028_bib19","doi-asserted-by":"crossref","first-page":"7532","DOI":"10.1167\/iovs.13-12795","article-title":"The economic cost of myopia in adults aged over 40 years in Singapore","volume":"54","author":"Zheng","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2017.04.028_bib20","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0002-9394(81)90170-7","article-title":"Pathologic myopia and choroidal neovascularization","volume":"91","author":"Hotchkiss","year":"1981","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib21","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1136\/bjo.87.5.570","article-title":"Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularisation in pathological myopia","volume":"87","author":"Ohno-Matsui","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib22","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000339893","article-title":"Myopic maculopathy: a review","volume":"228","author":"Silva","year":"2012","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.ophtha.2017.04.028_bib23","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0161-6420(01)00544-9","article-title":"Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial\u2014VIP report no. 1","volume":"108","year":"2001","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.04.028_bib24","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ophtha.2013.10.023","article-title":"RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia","volume":"121","author":"Wolf","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.04.028_bib25","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S0161-6420(01)01007-7","article-title":"Long-term visual prognosis of choroidal neovascularization in high myopia: a comparison between age groups","volume":"109","author":"Yoshida","year":"2002","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.04.028_bib26","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1097\/IAE.0b013e318285cc24","article-title":"Ocular risk factors for recurrence of myopic choroidal neovascularization: long-term follow-up study","volume":"33","author":"Kang","year":"2013","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.04.028_bib27","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1167\/iovs.09-3493","article-title":"Ocular risk factors for choroidal neovascularization in pathologic myopia","volume":"51","author":"Ikuno","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2017.04.028_bib28","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1097\/IAE.0b013e318174417a","article-title":"Lacquer crack formation and choroidal neovascularization in pathologic myopia","volume":"28","author":"Ikuno","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.04.028_bib29","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1097\/IAE.0000000000000015","article-title":"Macular choroidal volume variations in highly myopic eyes with myopic traction maculopathy and choroidal neovascularization","volume":"34","author":"Barteselli","year":"2014","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.04.028_bib30","doi-asserted-by":"crossref","first-page":"e580","DOI":"10.1111\/aos.12117","article-title":"Choroidal thickness and risk characteristics of eyes with myopic choroidal neovascularization","volume":"91","author":"Cheung","year":"2013","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib31","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/eye.2011.94","article-title":"The analysis of lacquer crack in the assessment of myopic choroidal neovascularization","volume":"25","author":"Kim","year":"2011","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2017.04.028_bib32","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1136\/bjo.2009.163535","article-title":"Choroidal filling delay in choroidal neovascularisation due to pathological myopia","volume":"94","author":"Wakabayashi","year":"2010","journal-title":"Br J Ophthalmol"},{"issue":"6 Suppl","key":"10.1016\/j.ophtha.2017.04.028_bib33","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.3928\/15428877-20121001-02","article-title":"Choroidal thickness measurement in highly myopic eyes using SD-OCT","volume":"43","author":"El Matri","year":"2012","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"10.1016\/j.ophtha.2017.04.028_bib34","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3341\/kjo.2006.20.1.18","article-title":"Indocyanine green angiographic features of myopic subfoveal choroidal neovascularization as a prognostic factor after photodynamic therapy","volume":"20","author":"Byeon","year":"2006","journal-title":"Korean J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib35","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/OPX.0b013e31828daa6e","article-title":"C-reactive protein and complement components in patients with pathological myopia","volume":"90","author":"Long","year":"2013","journal-title":"Optom Vis Sci"},{"key":"10.1016\/j.ophtha.2017.04.028_bib36","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ajo.2005.10.012","article-title":"Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization","volume":"141","author":"Tong","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib37","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/IAE.0000000000000311","article-title":"Associations of inflammatory cytokines with choroidal neovascularization in highly myopic eyes","volume":"35","author":"Yamamoto","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.04.028_bib38","doi-asserted-by":"crossref","first-page":"5004","DOI":"10.1167\/iovs.12-9538","article-title":"Genetic factors for choroidal neovascularization associated with high myopia","volume":"53","author":"Leveziel","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2017.04.028_bib39","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1167\/iovs.13-12280","article-title":"Evaluation of pigment epithelium-derived factor and complement factor I polymorphisms as a cause of choroidal neovascularization in highly myopic eyes","volume":"54","author":"Miyake","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2017.04.028_bib40","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ophtha.2013.06.043","article-title":"Vascular endothelial growth factor gene and the response to anti-vascular endothelial growth factor treatment for choroidal neovascularization in high myopia","volume":"121","author":"Miyake","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.04.028_bib41","doi-asserted-by":"crossref","first-page":"1632.e1","DOI":"10.1016\/j.ophtha.2008.03.004","article-title":"Myopic choroidal neovascularization genetics","volume":"115","author":"Fernandez-Robredo","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.04.028_bib42","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/eye.2009.215","article-title":"ARMS2\/HTRA1 and CFH polymorphisms are not associated with choroidal neovascularization in highly myopic eyes of the elderly Japanese population","volume":"24","author":"Nakanishi","year":"2010","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2017.04.028_bib43","doi-asserted-by":"crossref","first-page":"7492","DOI":"10.1167\/iovs.13-12825","article-title":"Association between ZIC2, RASGRF1, and SHISA6 genes and high myopia in Japanese subjects","volume":"54","author":"Oishi","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2017.04.028_bib44","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1167\/iovs.11-9405","article-title":"Vascular endothelial growth factor gene polymorphisms and choroidal neovascularization in highly myopic eyes","volume":"53","author":"Akagi-Kurashige","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2017.04.028_bib45","first-page":"257381","article-title":"Aqueous concentrations of vascular endothelial growth factor in eyes with high myopia with and without choroidal neovascularization","volume":"2013","author":"Wakabayashi","year":"2013","journal-title":"J\u00a0Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib46","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1136\/bjo.86.7.771","article-title":"Retrobulbar circulation in myopic patients with or without myopic choroidal neovascularisation","volume":"86","author":"Dimitrova","year":"2002","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib47","doi-asserted-by":"crossref","first-page":"4868","DOI":"10.1167\/iovs.12-9919","article-title":"Prevalence and associated risk factors of myopic maculopathy in elderly Chinese: the Shihpai Eye Study","volume":"53","author":"Chen","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2017.04.028_bib48","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/S0161-6420(03)00461-5","article-title":"Myopic choroidal neovascularization: a 10-year follow-up","volume":"110","author":"Yoshida","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.04.028_bib49","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00417-004-0960-5","article-title":"Characteristics of patients with a favorable natural course of myopic choroidal neovascularization","volume":"243","author":"Hayashi","year":"2005","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib50","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1136\/bjo.2005.081992","article-title":"Visual outcomes for high myopic patients with or without myopic maculopathy: a 10 year follow up study","volume":"90","author":"Shih","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib51","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/S0161-6420(84)34116-1","article-title":"Natural history of choroidal neovascularization in degenerative myopia","volume":"91","author":"Avila","year":"1984","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.04.028_bib52","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ajo.2007.08.029","article-title":"Development of macular hole and macular retinoschisis in eyes with myopic choroidal neovascularization","volume":"145","author":"Shimada","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib53","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.ophtha.2009.11.003","article-title":"Long-term pattern of progression of myopic maculopathy: a natural history study","volume":"117","author":"Hayashi","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.04.028_bib54","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.ajo.2012.11.021","article-title":"Angiographic and optical coherence tomography characteristics of recent myopic choroidal neovascularization","volume":"155","author":"Leveziel","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib55","series-title":"System of Ophthalmology: Ophthalmic Optics and Refraction","first-page":"297","article-title":"Pathological refractive errors","author":"Duke-Elder","year":"1970"},{"key":"10.1016\/j.ophtha.2017.04.028_bib56","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1755-3768.1988.tb02681.x","article-title":"On the definition of pathologic myopia in group studies","volume":"185","author":"Tokoro","year":"1988","journal-title":"Acta Ophthalmol Suppl"},{"key":"10.1016\/j.ophtha.2017.04.028_bib57","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.1097\/OPX.0b013e3181940655","article-title":"Molecular genetics of human myopia: an update","volume":"86","author":"Young","year":"2009","journal-title":"Optom Vis Sci"},{"key":"10.1016\/j.ophtha.2017.04.028_bib58","series-title":"Pathologic Myopia","first-page":"83","article-title":"Update on the pathology of pathological myopia","author":"Rashid","year":"2014"},{"key":"10.1016\/j.ophtha.2017.04.028_bib59","series-title":"Pathologic Myopia","first-page":"75","article-title":"Public health impact of pathologic myopia","author":"Chiang","year":"2014"},{"key":"10.1016\/j.ophtha.2017.04.028_bib60","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1475-1313.2005.00298.x","article-title":"Myopia and associated pathological complications","volume":"25","author":"Saw","year":"2005","journal-title":"Ophthalmic Physiol Opt"},{"key":"10.1016\/j.ophtha.2017.04.028_bib61","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ajo.2015.01.022","article-title":"International photographic classification and grading system for myopic maculopathy","volume":"159","author":"Ohno-Matsui","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib62","series-title":"Atlas of Posterior Fundus Changes in Pathologic Myopia","author":"Tokoro","year":"1998"},{"key":"10.1016\/j.ophtha.2017.04.028_bib63","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1136\/bjo.2008.138198","article-title":"Abnormal fundus autofluorescence patterns in myopic choroidal neovascularisation","volume":"92","author":"Sawa","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib64","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0161-6420(83)80018-9","article-title":"Visual prognosis of disciform degeneration in myopia","volume":"90","author":"Hampton","year":"1983","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.04.028_bib65","doi-asserted-by":"crossref","first-page":"630","DOI":"10.2174\/138945010791011929","article-title":"Treatment of choroidal neovascularization in high myopia","volume":"11","author":"Montero","year":"2010","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.ophtha.2017.04.028_bib66","series-title":"Pathologic Myopia","first-page":"211","article-title":"Choroidal neovascularization","author":"Spaide","year":"2014"},{"key":"10.1016\/j.ophtha.2017.04.028_bib67","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.ajo.2011.03.002","article-title":"Characteristics of periconus choroidal neovascularization in pathologic myopia","volume":"152","author":"Nagaoka","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib68","first-page":"CD004765","article-title":"Laser photocoagulation for choroidal neovascularisation in pathologic myopia","author":"Virgili","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ophtha.2017.04.028_bib69","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1034\/j.1600-0420.2002.800116.x","article-title":"Optical coherence tomography of choroidal neovascularization in high myopia","volume":"80","author":"Baba","year":"2002","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.ophtha.2017.04.028_bib70","doi-asserted-by":"crossref","first-page":"245","DOI":"10.4103\/0974-9233.58422","article-title":"Inflammatory choroidal neovascularization","volume":"16","author":"Neri","year":"2009","journal-title":"Middle East Afr J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib71","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/S0161-6420(96)30515-0","article-title":"Etiology of choroidal neovascularization in young patients","volume":"103","author":"Cohen","year":"1996","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.04.028_bib72","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0161-6420(95)30968-2","article-title":"The natural history of idiopathic subfoveal choroidal neovascularization","volume":"102","author":"Ho","year":"1995","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.04.028_bib73","doi-asserted-by":"crossref","first-page":"e53660","DOI":"10.1371\/journal.pone.0053660","article-title":"Choroidal thickness and biometric markers for the screening of lacquer cracks in patients with high myopia","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ophtha.2017.04.028_bib74","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000358331","article-title":"Fluorescein angiography and spectral-domain optical coherence tomography for monitoring anti-VEGF therapy in myopic choroidal neovascularization","volume":"52","author":"Iacono","year":"2014","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.ophtha.2017.04.028_bib75","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1055\/s-0035-1545817","article-title":"Long-term follow-up of choroidal neovascularization in pathological myopia treated with intravitreal ranibizumab","volume":"232","author":"Ladaique","year":"2015","journal-title":"Klin Monbl Augenheilkd"},{"key":"10.1016\/j.ophtha.2017.04.028_bib76","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3928\/1542-8877-20040301-09","article-title":"Indocyanine green angiography in high myopia","volume":"35","author":"Axer-Siegel","year":"2004","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"10.1016\/j.ophtha.2017.04.028_bib77","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1136\/bjo.2005.085555","article-title":"Optical coherence tomography to monitor photodynamic therapy in pathological myopia","volume":"90","author":"Garc\u00eda-Layana","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib78","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/eye.2012.75","article-title":"Spectral-domain OCT in anti-VEGF treatment of myopic choroidal neovascularization","volume":"26","author":"Introini","year":"2012","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2017.04.028_bib79","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000357980","article-title":"Imaging of naive myopic choroidal neovascularization by spectral-domain optical coherence tomography","volume":"232","author":"Milani","year":"2014","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.ophtha.2017.04.028_bib80","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1167\/iovs.12-11184","article-title":"Noninvasive investigation of deep vascular pathologies of exudative macular diseases by high-penetration optical coherence angiography","volume":"54","author":"Hong","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2017.04.028_bib81","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s10792-015-0118-y","article-title":"Optical coherence tomography and pathological myopia: an update of the literature","volume":"35","author":"Cicinelli","year":"2015","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib82","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ajo.2015.11.014","article-title":"Macular Bruch membrane holes in choroidal neovascularization-related myopic macular atrophy by swept-source optical coherence tomography","volume":"162","author":"Ohno-Matsui","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib83","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1007\/s00417-013-2282-y","article-title":"Sensitivity of fluorescein angiography alone or with SD-OCT for the diagnosis of myopic choroidal neovascularization","volume":"251","author":"Milani","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib84","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ajo.2015.04.030","article-title":"Fundus autofluorescence changes after ranibizumab treatment for subfoveal choroidal neovascularization secondary to pathologic myopia","volume":"160","author":"Parodi","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib85","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.survophthal.2014.10.002","article-title":"The other CNVM: a review of myopic choroidal neovascularization treatment in the age of anti-vascular endothelial growth factor agents","volume":"60","author":"Adatia","year":"2015","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib86","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2147\/OPTH.S49437","article-title":"Current and emerging treatment options for myopic choroidal neovascularization","volume":"9","author":"El Matri","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib87","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1136\/bjophthalmol-2014-305131","article-title":"Myopic choroidal neovascularisation: current concepts and update on clinical management","volume":"99","author":"Wong","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib88","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1097\/IAE.0b013e3181b1bb1a","article-title":"Anti-VEGF drugs as the 2009 first-line therapy for choroidal neovascularization in pathologic myopia","volume":"29","author":"Cohen","year":"2009","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.04.028_bib89","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00417-011-1889-0","article-title":"Recent trends in the management of maculopathy secondary to pathological myopia","volume":"250","author":"Mitry","year":"2012","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib90","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.2147\/DDDT.S87920","article-title":"Anti-VEGF treatment for myopic choroid neovascularization: from molecular characterization to update on clinical application","volume":"9","author":"Zhang","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.ophtha.2017.04.028_bib91","unstructured":"OCEBM Levels of Evidence Working Group. The Oxford Levels of Evidence 2. Oxford Centre for Evidence-Based Medicine, 2011. Available at: http:\/\/www.cebm.net\/index.aspx?o=5653. Accessed October 17,\u00a02014."},{"key":"10.1016\/j.ophtha.2017.04.028_bib92","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1097\/IAE.0b013e31827d260a","article-title":"Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization secondary to pathologic myopia: systematic review and meta-analysis","volume":"33","author":"Wang","year":"2013","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.04.028_bib93","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.ophtha.2015.01.025","article-title":"Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: the MYRROR study","volume":"122","author":"Ikuno","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.04.028_bib94","series-title":"Eylea-H-C-2392-II-0021: EPAR - Assessment Report - Variation","year":"2015"},{"key":"10.1016\/j.ophtha.2017.04.028_bib95","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1097\/01.iae.0000242842.14624.e7","article-title":"Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration","volume":"26","author":"Ferrara","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.04.028_bib96","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000333213","article-title":"Long-term follow-up of myopic choroidal neovascularization treated with ranibizumab","volume":"227","author":"Franqueira","year":"2012","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.ophtha.2017.04.028_bib97","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00417-008-0995-0","article-title":"Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization","volume":"247","author":"Konstantinidis","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib98","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/IAE.0b013e3181bcef24","article-title":"Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia","volume":"30","author":"Lalloum","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.04.028_bib99","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000328980","article-title":"Intravitreal ranibizumab for choroidal neovascularization secondary to pathological myopia: 12-month follow-up","volume":"226","author":"Lorenzo","year":"2011","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.ophtha.2017.04.028_bib100","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/eye.2009.88","article-title":"Intravitreal ranibizumab for choroidal neovascularization secondary to pathologic myopia: 12-month results","volume":"23","author":"Mon\u00e9s","year":"2009","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2017.04.028_bib101","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1097\/IAE.0b013e31817eda41","article-title":"Short-term efficacy and safety of intravitreal ranibizumab for myopic choroidal neovascularization","volume":"28","author":"Silva","year":"2008","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.04.028_bib102","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/IAE.0b013e3181c9691e","article-title":"Intravitreal ranibizumab for myopic choroidal neovascularization: 12-month results","volume":"30","author":"Silva","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.04.028_bib103","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1016\/j.ophtha.2013.06.010","article-title":"Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study","volume":"120","author":"Tufail","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.04.028_bib104","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/eye.2013.8","article-title":"Ranibizumab for the treatment of choroidal neovascularisation secondary to pathological myopia: interim analysis of the REPAIR study","volume":"27","author":"Tufail","year":"2013","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2017.04.028_bib105","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1136\/bjo.2009.174243","article-title":"Is ranibizumab effective in stopping the loss of vision for choroidal neovascularisation in pathologic myopia? A long-term follow-up study","volume":"95","author":"Vadal\u00e0","year":"2011","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib106","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.3760\/cma.j.issn.0366-6999.20132990","article-title":"Intravitreal ranibizumab for the treatment of pathological myopia associated with choroidal neovascularization in Chinese patients","volume":"127","author":"Yang","year":"2014","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.ophtha.2017.04.028_bib107","first-page":"1079","article-title":"Single intravitreal ranibizumab for myopic choroidal neovascularization","volume":"5","author":"Nor-Masniwati","year":"2011","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib108","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.ajo.2010.09.021","article-title":"Intravitreal ranibizumab for myopic choroidal neovascularization: factors predictive of visual outcome and need for retreatment","volume":"151","author":"Calvo-Gonzalez","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib109","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/IAE.0b013e31819ed6bd","article-title":"Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia","volume":"29","author":"Lai","year":"2009","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.04.028_bib110","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1089\/jop.2011.0106","article-title":"The 12-month outcome of three consecutive monthly intravitreal injections of ranibizumab for myopic choroidal neovascularization","volume":"28","author":"Wu","year":"2012","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.ophtha.2017.04.028_bib111","doi-asserted-by":"crossref","first-page":"e615","DOI":"10.1111\/aos.12457","article-title":"One-year outcome of two different initial dosing regimens of intravitreal ranibizumab for myopic choroidal neovascularization","volume":"92","author":"Kung","year":"2014","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib112","doi-asserted-by":"crossref","first-page":"e0128403","DOI":"10.1371\/journal.pone.0128403","article-title":"Treatment satisfaction and well-being in patients with myopic choroidal neovascularization treated with ranibizumab in the REPAIR study","volume":"10","author":"Amoaku","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ophtha.2017.04.028_bib113","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1097\/IAE.0000000000000201","article-title":"Long-term functional and morphologic retinal changes after ranibizumab and photodynamic therapy in myopic choroidal neovascularization","volume":"34","author":"Parravano","year":"2014","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.04.028_bib114","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000369397","article-title":"Intravitreal ranibizumab for the treatment of choroidal neovascularizations associated with pathologic myopia: a prospective study","volume":"233","author":"Pasyechnikova","year":"2015","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.ophtha.2017.04.028_bib115","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s10384-014-0363-z","article-title":"Long-term variable outcome of myopic choroidal neovascularization treated with ranibizumab","volume":"59","author":"Cohen","year":"2015","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib116","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1055\/s-0032-1328366","article-title":"Three years follow-up results of ranibizumab treatment for choroidal neovascularization secondary to pathologic myopia","volume":"230","author":"Hefner","year":"2013","journal-title":"Klin Monbl Augenheilkd"},{"key":"10.1016\/j.ophtha.2017.04.028_bib117","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1471-2415-14-69","article-title":"Comparison of 1-year therapeutic effect of ranibizumab and bevacizumab for myopic choroidal neovascularization: a retrospective, multicenter, comparative study","volume":"14","author":"Cha","year":"2014","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib118","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ajo.2009.10.010","article-title":"Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab\u2014a randomized controlled trial","volume":"149","author":"Gharbiya","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib119","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1007\/s00417-014-2886-x","article-title":"A\u00a0randomized trial of intravitreal bevacizumab vs. ranibizumab for myopic CNV","volume":"253","author":"Pece","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib120","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1097\/IAE.0b013e31826956b7","article-title":"Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization","volume":"32","author":"Iacono","year":"2012","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.04.028_bib121","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/eye.2012.97","article-title":"Long-term outcome of intravitreal anti-vascular endothelial growth factor therapy with bevacizumab or ranibizumab as primary treatment for subfoveal myopic choroidal neovascularization","volume":"26","author":"Lai","year":"2012","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2017.04.028_bib122","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1097\/IAE.0000000000000632","article-title":"Intravitreal anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to pathologic myopia: six years outcome","volume":"35","author":"Ruiz-Moreno","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.04.028_bib123","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/IAE.0b013e3181bd2fe4","article-title":"Intravitreal anti-VEGF versus photodynamic therapy with verteporfin for treatment of myopic choroidal neovascularization","volume":"30","author":"Yoon","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.04.028_bib124","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000357290","article-title":"Progression of myopic maculopathy after treatment of choroidal neovascularization","volume":"231","author":"Farinha","year":"2014","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.ophtha.2017.04.028_bib125","doi-asserted-by":"crossref","first-page":"887","DOI":"10.5301\/ejo.5000323","article-title":"Choroidal thickness after treatment for myopic choroidal neovascularization","volume":"23","author":"Farinha","year":"2013","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib126","doi-asserted-by":"crossref","first-page":"23","DOI":"10.5693\/djo.01.2011.05.003","article-title":"Combined intravitreal ranibizumab and verteporfin photodynamic therapy versus ranibizumab alone for the treatment of age-related macular degeneration","volume":"17","author":"Giustolisi","year":"2011","journal-title":"Digit J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib127","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1089\/jop.2011.0023","article-title":"Intravitreal injection of 2.5\u00a0mg bevacizumab for treatment of myopic choroidal neovascularization in treatment-naive cases: a 2-year follow-up","volume":"27","author":"Chen","year":"2011","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.ophtha.2017.04.028_bib128","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1038\/eye.2008.404","article-title":"Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up","volume":"23","author":"Wu","year":"2009","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2017.04.028_bib129","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1136\/bjo.2007.130260","article-title":"Intravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to pathological myopia: 6-month results","volume":"92","author":"Arias","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib130","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.ophtha.2007.03.043","article-title":"Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study","volume":"114","author":"Chan","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.04.028_bib131","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1177\/112067210701700422","article-title":"Intravitreal bevacizumab (Avastin) as primary treatment for myopic choroidal neovascularization","volume":"17","author":"Mandal","year":"2007","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib132","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/sj.eye.6703052","article-title":"Intravitreous bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: short-term results","volume":"23","author":"Ruiz-Moreno","year":"2009","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2017.04.028_bib133","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/IAE.0b013e3182681066","article-title":"Multifocal electroretinography and optical coherence tomography changes after repeated intravitreal bevacizumab (Avastin) in myopic choroidal neovascularization","volume":"33","author":"Sabry","year":"2013","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.04.028_bib134","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3928\/15428877-20080501-14","article-title":"Intravitreal bevacizumab for myopic choroidal neovascularization","volume":"39","author":"Rensch","year":"2008","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"10.1016\/j.ophtha.2017.04.028_bib135","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1136\/bjo.2008.145797","article-title":"Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study","volume":"93","author":"Chan","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib136","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ajo.2008.07.022","article-title":"Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results","volume":"147","author":"Gharbiya","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib137","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.2147\/OPTH.S34649","article-title":"Only first intravitreal bevacizumab injection achieves statistically significant visual improvement in na\u00efve myopic choroidal neovascularization","volume":"6","author":"Milani","year":"2012","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib138","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1097\/IAE.0b013e3181e22659","article-title":"Twelve-month outcome after one intravitreal injection of bevacizumab to treat myopic choroidal neovascularization","volume":"30","author":"Ruiz-Moreno","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.04.028_bib139","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1111\/j.1755-3768.2010.02070.x","article-title":"Three versus one intravitreal bevacizumab injections as initial protocol to treat myopic choroidal neovascularization","volume":"90","author":"Ruiz-Moreno","year":"2012","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib140","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1136\/bjo.2008.145391","article-title":"Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome","volume":"93","author":"Ruiz-Moreno","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib141","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/IAE.0000000000000332","article-title":"Comparison of visual prognoses between natural course of simple hemorrhage and choroidal neovascularization treated with intravitreal bevacizumab in highly myopic eyes: a 1-year follow-up","volume":"35","author":"Goto","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.04.028_bib142","first-page":"39","article-title":"Intravitreal bevacizumab for myopic choroidal neovascularization: 1-year and 2-year results","author":"Coppens","year":"2010","journal-title":"Bull Soc Belge Ophtalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib143","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ajo.2008.07.017","article-title":"Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: one-year results","volume":"147","author":"Ikuno","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib144","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1016\/j.ophtha.2011.07.029","article-title":"Myopic choroidal neovascularization","volume":"118","author":"Ruiz-Moreno","year":"2011","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.04.028_bib145","first-page":"17","article-title":"Intravitreal bevacizumab for myopic choroidal neovascularization: short-term and 1-year results","author":"Spielberg","year":"2009","journal-title":"Bull Soc Belge Ophtalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib146","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/IAE.0b013e3182278bae","article-title":"Two-year outcomes of intravitreal bevacizumab for choroidal neovascularization in Japanese patients with pathologic myopia","volume":"32","author":"Hayashi","year":"2012","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.04.028_bib147","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/eye.2010.226","article-title":"Prognostic factors for visual outcomes 2-years after intravitreal bevacizumab for myopic choroidal neovascularization","volume":"25","author":"Nakanishi","year":"2011","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.ophtha.2017.04.028_bib148","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.ajo.2013.08.002","article-title":"Prognostic factors of eyes with na\u00efve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab","volume":"156","author":"Yang","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib149","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1136\/bjophthalmol-2012-301639","article-title":"Long-term results of intravitreal bevacizumab for choroidal neovascularisation in pathological myopia","volume":"96","author":"Gharbiya","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00417-012-2022-8","article-title":"Long-term effect of intravitreal injection of anti-VEGF agent for visual acuity and chorioretinal atrophy progression in myopic choroidal neovascularization","volume":"251","author":"Oishi","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib151","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jcjo.2011.12.009","article-title":"Intravitreal bevacizumab as a treatment for choroidal neovascularisation secondary to myopia: 4-year study results","volume":"47","author":"Peiretti","year":"2012","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib152","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00417-014-2721-4","article-title":"Forty-two-month outcome of intravitreal bevacizumab in myopic choroidal neovascularization","volume":"253","author":"Traversi","year":"2015","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib153","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00417-015-3076-1","article-title":"Intravitreal bevacizumab for choroidal neovascularization due to pathologic myopia: long-term outcomes","volume":"254","author":"Sarao","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib154","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s00417-010-1340-y","article-title":"Intravitreal bevacizumab to treat myopic choroidal neovascularization: 2-year outcome","volume":"248","author":"Ruiz-Moreno","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib155","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000360307","article-title":"Anti-VEGF therapy in myopic choroidal neovascularization: long-term results","volume":"232","author":"Freitas-da-Costa","year":"2014","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.ophtha.2017.04.028_bib156","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1136\/bjophthalmol-2012-302973","article-title":"Intravitreal anti-VEGF therapy for choroidal neovascularisation secondary to pathological myopia: 4-year outcome","volume":"97","author":"Ruiz-Moreno","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib157","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/IAE.0b013e31826b6731","article-title":"Intravitreal bevacizumab for extrafoveal choroidal neovascularization secondary to pathologic myopia","volume":"33","author":"Parodi","year":"2013","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.04.028_bib158","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1097\/IAE.0b013e3181c59725","article-title":"Macular functional changes evaluated with MP-1 microperimetry after intravitreal bevacizumab for subfoveal myopic choroidal neovascularization: one-year results","volume":"30","author":"Scupola","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.04.028_bib159","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.ajo.2008.11.020","article-title":"Central retinal sensitivity after intravitreal injection of bevacizumab for myopic choroidal neovascularization","volume":"147","author":"Yodoi","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib160","doi-asserted-by":"crossref","first-page":"210","DOI":"10.5301\/EJO.2011.7750","article-title":"Comparison between anti-vascular endothelial growth factor therapy and photodynamic therapy for myopic choroidal neovascularization","volume":"22","author":"Matsuo","year":"2012","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib161","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1136\/bjo.2009.166025","article-title":"Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation","volume":"94","author":"Baba","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib162","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.ophtha.2013.03.006","article-title":"Intravitreal bevacizumab in myopic neovascular membranes: 24-month results","volume":"120","author":"Ruiz-Moreno","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.04.028_bib163","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/archophthalmol.2009.408","article-title":"Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia","volume":"128","author":"Parodi","year":"2010","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib164","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s00417-011-1654-4","article-title":"Intravitreal bevacizumab versus photodynamic therapy for myopic choroidal neovascularization in a North-African population","volume":"249","author":"El Matri","year":"2011","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib165","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ajo.2009.08.008","article-title":"Two-year visual results for older Asian women treated with photodynamic therapy or bevacizumab for myopic choroidal neovascularization","volume":"149","author":"Ikuno","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib166","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ajo.2009.03.026","article-title":"Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy","volume":"148","author":"Hayashi","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib167","first-page":"335","article-title":"Combined therapy with bevacizumab and photodynamic therapy for myopic choroidal neovascularization: a one-year follow-up controlled study","volume":"7","author":"Saviano","year":"2014","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib168","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00417-009-1285-1","article-title":"Bevacizumab for choroidal neovascularization secondary to pathologic myopia: is there a decline of the treatment efficacy after 2 years?","volume":"248","author":"Voykov","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib169","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1517\/13543784.14.5.671","article-title":"Pegaptanib sodium for the treatment of neovascular age-related macular degeneration","volume":"14","author":"Moshfeghi","year":"2005","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ophtha.2017.04.028_bib170","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s00417-006-0472-6","article-title":"Pegaptanib for myopic choroidal neovascularization in a young patient","volume":"245","author":"Bennett","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib171","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/IAE.0b013e318261a73c","article-title":"Intravitreal pegaptanib sodium (Macugen) for treatment of myopic choroidal neovascularization: a morphologic and functional study","volume":"33","author":"Rinaldi","year":"2013","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.04.028_bib172","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1167\/iovs.12-11542","article-title":"Association between choroidal morphology and anti-vascular endothelial growth factor treatment outcome in myopic choroidal neovascularization","volume":"54","author":"Ahn","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2017.04.028_bib173","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1007\/s00417-012-2159-5","article-title":"Summary of prognostic factors for choroidal neovascularization due to pathological myopia treated by intravitreal bevacizumab injection","volume":"250","author":"Wang","year":"2012","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib174","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1097\/IAE.0b013e31821ba2dc","article-title":"Predictive factors for visual outcome to intravitreal bevacizumab in young Chinese patients with myopic choroidal neovascularization","volume":"31","author":"Kuo","year":"2011","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.04.028_bib175","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1097\/IAE.0b013e318227aa09","article-title":"Prognostic factors for visual outcome after intravitreal anti-VEGF injection for naive myopic choroidal neovascularization","volume":"32","author":"Yoon","year":"2012","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.04.028_bib176","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00417-011-1921-4","article-title":"Factors associated with enlargement of chorioretinal atrophy after intravitreal bevacizumab for myopic choroidal neovascularization","volume":"250","author":"Uemoto","year":"2012","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"Suppl 1","key":"10.1016\/j.ophtha.2017.04.028_bib177","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.4103\/0976-500X.120947","article-title":"Anti-vascular endothelial growth factor drugs safety and efficacy in ophthalmic diseases","volume":"4","author":"Ventrice","year":"2013","journal-title":"J\u00a0Pharmacol Pharmacother"},{"key":"10.1016\/j.ophtha.2017.04.028_bib178","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.3760\/cma.j.issn.0366-6999.20130188","article-title":"Anti-vascular endothelial growth factor: the future treatment of choroidal neovascularization in pathologic myopia?","volume":"126","author":"Zhu","year":"2013","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.ophtha.2017.04.028_bib179","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1517\/14712598.2014.967210","article-title":"Bevacizumab for choroidal neovascularization secondary to age-related macular degeneration and pathological myopia","volume":"14","author":"Hashemi","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.ophtha.2017.04.028_bib180","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s10792-007-9152-8","article-title":"Vitritis in the contralateral uninjected eye following intravitreal bevacizumab (Avastin)","volume":"28","author":"Neri","year":"2008","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib181","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s10384-011-0034-2","article-title":"Macular detachment after successful intravitreal bevacizumab for myopic choroidal neovascularization","volume":"55","author":"Shimada","year":"2011","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib182","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.3760\/cma.j.issn.0366-6999.20133045","article-title":"Retinoschisis and intravitreal ranibizumab treatment for myopic choroidal neovascularization","volume":"127","author":"Huang","year":"2014","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.ophtha.2017.04.028_bib183","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.3109\/02713683.2014.990638","article-title":"Changes in clotting time, plasma fibrinogen levels, and blood viscosity after administration of ranibizumab for treatment of choroidal neovascularization","volume":"40","author":"Yi","year":"2015","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.ophtha.2017.04.028_bib184","doi-asserted-by":"crossref","first-page":"143","DOI":"10.47102\/annals-acadmedsg.V39N2p143","article-title":"Inadvertent use of bevacizumab to treat choroidal neovascularisation during pregnancy: a case report","volume":"39","author":"Wu","year":"2010","journal-title":"Ann Acad Med Singapore"},{"key":"10.1016\/j.ophtha.2017.04.028_bib185","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1089\/jop.2012.0067","article-title":"Intravitreal bevacizumab for a subfoveal myopic choroidal neovascularization in the first trimester of pregnancy","volume":"28","author":"Introini","year":"2012","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.ophtha.2017.04.028_bib186","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1097\/IAE.0b013e3181f57d58","article-title":"Intravitreal bevacizumab during pregnancy","volume":"30","author":"Tarantola","year":"2010","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.04.028_bib187","doi-asserted-by":"crossref","first-page":"e136","DOI":"10.1111\/j.1755-3768.2009.01572.x","article-title":"Early loss of pregnancy after intravitreal bevacizumab injection","volume":"88","author":"Petrou","year":"2010","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib188","first-page":"2566","article-title":"Changes in refraction over 10 years in an adult population: the Beaver Dam Eye study","volume":"43","author":"Lee","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.ophtha.2017.04.028_bib189","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s004170050281","article-title":"Surgical removal of subfoveal choroidal neovascular membranes in high myopia","volume":"237","author":"Bottoni","year":"1999","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib190","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s10792-013-9761-3","article-title":"Surgical removal of subfoveal choroidal neovascularization in pathologic myopia: a 12-year follow-up study","volume":"33","author":"Hera","year":"2013","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib191","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1136\/bjo.85.9.1041","article-title":"Surgical removal of subfoveal choroidal neovascularisation in highly myopic patients","volume":"85","author":"Ruiz-Moreno","year":"2001","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib192","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1136\/bjo.2005.074716","article-title":"Choroidal neovascularisation in pathological myopia: an update in management","volume":"89","author":"Chan","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib193","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1097\/IAE.0b013e31820668cf","article-title":"Treatment of non-age-related macular degeneration submacular diseases with macular translocation surgery","volume":"31","author":"Ehlers","year":"2011","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.04.028_bib194","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0002-9394(00)00582-1","article-title":"Comparison of visual function after foveal translocation with 360 degrees retinotomy and with scleral shortening in a patient with bilateral myopic neovascular maculopathy","volume":"130","author":"Fujikado","year":"2000","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib195","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0002-9394(00)00770-4","article-title":"Visual function after foveal translocation with 360-degree retinotomy and simultaneous torsional muscle surgery in patients with myopic neovascular maculopathy","volume":"131","author":"Fujikado","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib196","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ajo.2006.09.041","article-title":"Photodynamic therapy vs limited macular translocation in the management of subfoveal choroidal neovascularization in pathologic myopia: a two-year study","volume":"143","author":"Glacet-Bernard","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib197","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S0002-9394(02)01335-1","article-title":"Surgical treatment of subfoveal neovascularization in myopia: macular translocation vs surgical removal","volume":"133","author":"Hamelin","year":"2002","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib198","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/00006982-199010000-00002","article-title":"Photocoagulation scar expansion after laser therapy for choroidal neovascularization in degenerative myopia","volume":"10","author":"Brancato","year":"1990","journal-title":"Retina"},{"key":"10.1016\/j.ophtha.2017.04.028_bib199","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/112067210201200207","article-title":"Long-term visual acuity after argon green laser photocoagulation of juxtafoveal choroidal neovascularization in highly myopic eyes","volume":"12","author":"Ruiz-Moreno","year":"2002","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib200","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1177\/112067219700700401","article-title":"Long-term visual outcome of choroidal neovascularization in pathologic myopia: natural history and laser treatment","volume":"7","author":"Secr\u00e9tan","year":"1997","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib201","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3928\/15428877-20091230-02","article-title":"Transpupillary thermotherapy of subfoveal choroidal neovascularization secondary to pathologic myopia","volume":"41","author":"Nabawi","year":"2010","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"10.1016\/j.ophtha.2017.04.028_bib202","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s10792-006-9010-0","article-title":"Transpupillary thermotherapy for myopic choroidal neovascularization: 1-year follow-up: TTT for myopic CNV","volume":"26","author":"Ozdek","year":"2005","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib203","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1442-9071.2008.01783.x","article-title":"Subthreshold transpupillary thermotherapy in Chinese patients with myopic choroidal neovascularization: one- and two-year follow up","volume":"36","author":"Wu","year":"2008","journal-title":"Clin Experiment Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib204","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0161-6420(02)01998-X","article-title":"Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial\u2014VIP report no. 3","volume":"110","author":"Blinder","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2017.04.028_bib205","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.ajo.2004.04.055","article-title":"Prognostic factors influencing visual outcome of photodynamic therapy for subfoveal choroidal neovascularization in pathologic myopia","volume":"138","author":"Ergun","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib206","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1136\/bjo.87.2.173","article-title":"Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularisation","volume":"87","author":"Montero","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib207","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1001\/archopht.123.10.1347","article-title":"Complications after photodynamic therapy","volume":"123","author":"Schnurrbusch","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib208","first-page":"CD002030","article-title":"Photodynamic therapy for neovascular age-related macular degeneration","author":"Wormald","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ophtha.2017.04.028_bib209","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1007\/s00417-004-0904-0","article-title":"Early neovascular bridging after photodynamic therapy of myopic choroidal neovascularization","volume":"242","author":"Lanzetta","year":"2004","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib210","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0002-9394(02)02257-2","article-title":"Selective occlusion of subfoveal choroidal neovascularization in pathologic myopia using a new technique of ingrowth site treatment","volume":"135","author":"Costa","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib211","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/j.1600-0420.2006.00745.x","article-title":"Trans-Tenon's retrobulbar triamcinolone infusion for myopic choroidal neovascularization","volume":"84","author":"Kojima","year":"2006","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.ophtha.2017.04.028_bib212","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ajo.2009.05.026","article-title":"Intravitreal bevacizumab vs sub-tenon triamcinolone acetonide for choroidal neovascularization attributable to pathologic myopia","volume":"148","author":"Wakabayashi","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib213","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2174\/138945011794182746","article-title":"Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration","volume":"12","author":"Becerra","year":"2011","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.ophtha.2017.04.028_bib214","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/j.1600-0420.2005.00506.x","article-title":"Photodynamic therapy in combination with intravitreal triamcinolone for myopic choroidal neovascularization","volume":"83","author":"Degenring","year":"2005","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.ophtha.2017.04.028_bib215","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ajo.2006.03.003","article-title":"Combined photodynamic therapy and intravitreal triamcinolone acetonide for the treatment of myopic subfoveal choroidal neovascularization","volume":"142","author":"Marticorena","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib216","doi-asserted-by":"crossref","first-page":"242","DOI":"10.4103\/0301-4738.81049","article-title":"Photodynamic monotherapy or combination treatment with intravitreal triamcinolone acetonide, bevacizumab or ranibizumab for choroidal neovascularization associated with pathological myopia","volume":"59","author":"Rishi","year":"2011","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib217","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1080\/08820530490520013","article-title":"Two-year results of macular translocation with scleral infolding in myopic choroidal neovascularisation","volume":"19","author":"Mateo","year":"2004","journal-title":"Semin Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib218","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1136\/bjo.2006.103606","article-title":"Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study","volume":"91","author":"Chan","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib219","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0002-9394(00)00769-8","article-title":"Initial experience of inferior limited macular translocation for subfoveal choroidal neovascularization resulting from causes other than age-related macular degeneration","volume":"131","author":"Fujii","year":"2001","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib220","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1089\/jop.2014.0033","article-title":"Two-year outcome of intravitreal injections of ranibizumab for myopic choroidal neovascularization","volume":"30","author":"Wu","year":"2014","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.ophtha.2017.04.028_bib221","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00417-003-0686-9","article-title":"Photodynamic therapy of subfoveal recurrences after laser photocoagulation of extrafoveal choroidal neovascularization in pathologic myopia","volume":"241","author":"Bandello","year":"2003","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2017.04.028_bib222","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s11684-007-0079-2","article-title":"Photodynamic therapy combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization","volume":"1","author":"Yu","year":"2007","journal-title":"Front Med China"},{"key":"10.1016\/j.ophtha.2017.04.028_bib223","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/eye.2008.17","article-title":"Photodynamic therapy combined with posterior subtenon triamcinolone acetonide injection in the treatment of choroidal neovascularization","volume":"23","author":"Lee","year":"2009","journal-title":"Eye (Lond)"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642017313015?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642017313015?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T23:50:46Z","timestamp":1719273046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642017313015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":222,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S0161642017313015"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2017.04.028","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myopic Choroidal Neovascularization","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2017.04.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}